XLO Stock Analysis
XL
Uncovered
Xilio Therapeutics Inc is uncovered by Eyestock quantitative analysis.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Low score
Xilio Therapeutics, Inc. operates as a biotechnology company. The company is headquartered in Waltham, Massachusetts and currently employs 89 full-time employees. The company went IPO on 2021-10-22. The firm has built its geographically precise solutions (GPS) platform to rapidly engineer molecules, including cytokines and other biologics. The Company’s most advanced product candidates are in clinical development. Its XTX101 is a clinical-stage, tumor-selective anti-CTLA-4 mAb, which is designed to improve upon the therapeutic index of existing anti-CTLA-4 therapies by localizing its activity in the TME. The company initiated a Phase I/II trial to evaluate XTX101 in patients with advanced solid tumors, and enrollment is ongoing. XTX202 is an engineered form of IL-2, which is masked with a protein domain to prevent binding activity until the protein domain is cleaved off by TME-associated proteases. The company initiated a Phase I/II trial to evaluate XTX202 in patients with solid tumors.